These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 30892965)

  • 1. Paces of Costly Care: Rare Disease Drug Access in Canada.
    McGuire M
    Med Anthropol; 2020; 39(4):319-332. PubMed ID: 30892965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alignment of health technology assessments and price negotiations for new drugs for rare disorders in Canada: Does it lead to improved patient access?
    Rawson NSB
    J Popul Ther Clin Pharmacol; 2020 Feb; 27(1):e48-e64. PubMed ID: 32124580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient Access to Medicines for Rare Diseases in European Countries.
    Detiček A; Locatelli I; Kos M
    Value Health; 2018 May; 21(5):553-560. PubMed ID: 29753352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug patent plan gets mixed reviews.
    Butler D
    Nature; 2009 Feb; 457(7233):1064. PubMed ID: 19256077
    [No Abstract]   [Full Text] [Related]  

  • 5. [Medicoeconomic data on rare disease drugs: a move towards more transparency?].
    Schwebig A; Duguet C; Ferry A; Bougé C; Fagon JY; Bismuth C; Ramon J
    Presse Med; 2012 May; 41 Suppl 1():S57-64. PubMed ID: 22487716
    [No Abstract]   [Full Text] [Related]  

  • 6. Small biotechs raring to cash in on the orphan disease market.
    Hersher R
    Nat Med; 2012 Mar; 18(3):330-1. PubMed ID: 22395682
    [No Abstract]   [Full Text] [Related]  

  • 7. A study of pharmaceutical data exclusivity laws in Latin America: is access to affordable medicine threatened?
    Cartagena RG; Attaran A
    Health Law J; 2009; 17():269-96. PubMed ID: 20608321
    [No Abstract]   [Full Text] [Related]  

  • 8. Access to medicines is not the business of the pharma industry.
    Brown PJ
    J Int Assoc Physicians AIDS Care (Chic); 2002; 1(1):9-11; discussion 12-4. PubMed ID: 12942664
    [No Abstract]   [Full Text] [Related]  

  • 9. Drug reimbursement policies in Canada--need for improved access to critical therapies.
    LeLorier J; Bell A; Bougher DJ; Cox JL; Turpie AG
    Ann Pharmacother; 2008 Jun; 42(6):869-73. PubMed ID: 18477735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pills, patents, and power: state creation of gray markets as a limit on patent rights.
    Ghosh S
    Fla J Int Law; 2002; 14(2):217-60. PubMed ID: 16526138
    [No Abstract]   [Full Text] [Related]  

  • 11. Balancing government regulation against access to drugs: address to Seton Hall University School of Law, February 16, 2007.
    Meron D
    Seton Hall Law Rev; 2007; 37(4):929-39. PubMed ID: 18363219
    [No Abstract]   [Full Text] [Related]  

  • 12. The Health Impact Fund: incentives for improving access to medicines.
    Banerjee A; Hollis A; Pogge T
    Lancet; 2010 Jan; 375(9709):166-9. PubMed ID: 20109894
    [No Abstract]   [Full Text] [Related]  

  • 13. Freebies for subject 641: a discussion of the ethical prospect of providing drug trial subjects with post-trial access to the drug tested--a Canadian perspective.
    Hutt LE
    Health Law J; 1998; 6 Spec No():169-87. PubMed ID: 14746066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A breakthrough in R&D for neglected diseases: new ways to get the drugs we need.
    Moran M
    PLoS Med; 2005 Sep; 2(9):e302. PubMed ID: 16138789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Global "hold-em".
    Cassidy BS
    Geriatr Nurs; 2006; 27(1):21-3. PubMed ID: 16483897
    [No Abstract]   [Full Text] [Related]  

  • 16. Will they deliver treatment access?: WTO rules and Canada's law on generic medicine exports.
    Elliott R
    HIV AIDS Policy Law Rev; 2006 Dec; 11(2-3):13-6. PubMed ID: 17373059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Jumpstarting research into neglected diseases.
    Leslie M
    Cell; 2006 Nov; 127(3):443-5. PubMed ID: 17081963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specialty Drugs - A Distinctly American Phenomenon.
    Naci H; Kesselheim AS
    N Engl J Med; 2020 Jun; 382(23):2179-2181. PubMed ID: 32492301
    [No Abstract]   [Full Text] [Related]  

  • 19. Universal access in Canada. Questions of equity remain.
    Wolfe S; Badgley RF
    Health PAC Bull; 1992; 22(3):29-35. PubMed ID: 10122938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA chief attacks Canada's drug price controls.
    Webster P
    Lancet; 2003 Nov; 362(9398):1816. PubMed ID: 14661624
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.